Refine by
Cytomx Lung Cancer Equipment & Supplies
2 equipment items found
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
In preclinical studies, Probody drug conjugates targeting CD166, have led to complete regressions in models of breast and lung cancer at therapeutically relevant doses, and are well tolerated in non-human primates. Updated Phase 1 results of CX-2009 in selected tumor types were announced at ASCO 2020 demonstrating durable clinical activity in HER2 negative ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
CytomX presented initial Phase 1 data at ASCO 2020 validating CD71 as a first-in-class oncology target with encouraging clinical activity observed. CytomX is preparing to advance the CX-2029 into 4 dose-expansion cohorts in patients with head and neck cancer, squamous non-small cell lung cancer, esophageal carcinoma, and diffuse large B cell ...